Puma Biotechnology News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.02.21	Puma Biotechnology und Pierre Fabre ändern die NERLYNX®-Lizenzvereinbarung, die neu auch Grosschina einbezieht (Businesswire)
25.02.21	Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China (Businesswire)
25.02.21	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Businesswire)
11.02.21	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
09.02.21	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
29.01.21	Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020 (Businesswire)
19.01.21	Puma Biotechnology to Present at the B. Riley Oncology Investor Conference (Businesswire)
15.01.21	Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT "Basket” Trial of Neratinib at ASCO GI (Businesswire)
05.01.21	Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference (Businesswire)
04.01.21	Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference (Businesswire)
11.12.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
11.12.20	Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS (Businesswire)
10.12.20	Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS (Businesswire)
09.12.20	Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 (Businesswire)
02.12.20	Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted (Businesswire)
17.11.20	Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) (Businesswire)
06.11.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.11.20	Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer (Businesswire)
05.11.20	Puma Biotechnology Reports Third Quarter 2020 Financial Results (Businesswire)
03.11.20	Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference (Businesswire)
22.10.20	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)
05.10.20	Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer (Businesswire)
02.10.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
08.09.20	Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference (Businesswire)
03.09.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
19.08.20	Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology (Businesswire)
10.08.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.08.20	Puma Biotechnology Reports Second Quarter 2020 Financial Results (Businesswire)
27.07.20	Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers (Businesswire)
23.07.20	Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results (Businesswire)
09.07.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.06.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
08.05.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.05.20	Puma Biotechnology Reports First Quarter 2020 Financial Results (Businesswire)
06.05.20	Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020 (Businesswire)
30.04.20	Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea (Businesswire)
23.04.20	Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results (Businesswire)
03.04.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
25.03.20	Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.03.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.02.20	Puma Biotechnology to Present at Cowen’s Annual Health Care Conference (Businesswire)
26.02.20	Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)
20.02.20	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Businesswire)
07.02.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.02.20	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results (Businesswire)
13.01.20	Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference (Businesswire)
09.01.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.01.20	Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference (Businesswire)
16.12.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
14.12.19	Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Puma Biotechnology Inc

Aktien Top/Flop

Meistgelesene Nachrichten